ClinicaltodayNew
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Alaunos Therapeutics terminated its screening study (NCT05124743), the data-collection protocol that HLA-typed and somatic-mutation-profiled patients with ovarian/endometrial, colorectal, pancreatic, NSCLC, and cholangiocarcinoma tumors to match them against the company's TCR library as the entry funnel into the TCR001-201 Phase I/II autologous TCR-T study. No therapy was administered under this protocol, and patients without a TCR match were discontinued. Termination closes the screening pipeline that fed the Phase I/II study — a meaningful operational signal for a library-matching approach where match rates gate enrollment.